GSK, one of the world's largest vaccine manufacturers, will take control of CureVac's leading experimental vaccines to fight infections, including seasonal flu and bird flu. It will pay CureVac 400 million euros ($430 million) upfront and up to 1.05 billion euros contingent on achievements.
CureVac N.V. ( NASDAQ:CVAC ) just released its latest quarterly report and things are not looking great. It was a...
CureVac ( NASDAQ:CVAC ) First Quarter 2024 Results Key Financial Results Revenue: €12.4m (up 74% from 1Q 2023). Net...